Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer - PubMed (original) (raw)
. 2013 Jun 25;108(12):2582-9.
doi: 10.1038/bjc.2013.248. Epub 2013 May 21.
Z H Yang, G Fisher, E Tikishvili, S Stone, J S Lanchbury, N Camacho, S Merson, D Brewer, C S Cooper, J Clark, D M Berney, H Møller, P Scardino, Z Sangale; Transatlantic Prostate Group
Collaborators, Affiliations
- PMID: 23695019
- PMCID: PMC3694239
- DOI: 10.1038/bjc.2013.248
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
J Cuzick et al. Br J Cancer. 2013.
Abstract
Background: The natural history of prostate cancer is highly variable and difficult to predict. We report on the prognostic value of phosphatase and tensin homologue (PTEN) loss in a cohort of 675 men with conservatively managed prostate cancer diagnosed by transurethral resection of the prostate.
Methods: The PTEN status was assayed by immunohistochemistry (PTEN IHC) and fluorescent in situ hybridisation (PTEN FISH). The primary end point was death from prostate cancer.
Results: The PTEN IHC loss was observed in 18% cases. This was significantly associated with prostate cancer death in univariate analysis (hazard ratio (HR)=3.51; 95% CI 2.60-4.73; P=3.1 × 10(-14)). It was highly predictive of prostate cancer death in the 50% of patients with a low risk score based on Gleason score, PSA, Ki-67 and extent of disease (HR=7.4; 95% CI 2.2-24.6; P=0.012) ), but had no prognostic value in the higher risk patients. The PTEN FISH loss was only weakly associated with PTEN IHC loss (κ=0.5). Both PTEN FISH loss and amplification were univariately predictive of death from prostate cancer, but this was not maintained in the multivariate analyses.
Conclusion: In low-risk patients, PTEN IHC loss adds prognostic value to Gleason score, PSA, Ki-67 and extent of disease.
Figures
Figure 1
Consort diagram: PTEN cohort derivation.
Figure 2
Prostatic adenocarcinoma showing PTEN-deficient (A) and PTEN-positive (B) staining by immunohistochemistry.
Figure 3
Univariate hazard ratios (95% CI) for PTEN IHC loss according to Gleason score (<7, =7 and >7), PSA (⩽10, 10–25 and >25 (ng ml−1)), Ki-67 (⩽5% and >5%), extent of disease (<21% and ⩾21%) and risk groups based on the clinical score (score<median, median<score<75% quantile, score >75% quantile). N, D and L denote the number at risk, deaths and PTEN loss counts in each subgroup.
Figure 4
Kaplan–Meier survival curves for PTEN IHC loss and normal PTEN divided by the median clinical score (low and high).
Figure 5
Histogram of the (normalised) clinical score based on the multivariate model using Gleason score, PSA, Ki-67 and extent of disease. The shaded area of each bar denotes the deaths in each clinical score bin. The arrows indicate the median score (36) and interquartile range (13–60).
Similar articles
- ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
Qi M, Yang X, Zhang F, Lin T, Sun X, Li Y, Yuan H, Ren Y, Zhang J, Qin X, Han B. Qi M, et al. PLoS One. 2014 Feb 7;9(2):e84959. doi: 10.1371/journal.pone.0084959. eCollection 2014. PLoS One. 2014. PMID: 24516518 Free PMC article. - Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA, Gray KP, Huang Y, Bowden M, Pomerantz M, Loda M, Sweeney CJ. Hamid AA, et al. Eur Urol Oncol. 2019 Sep;2(5):475-482. doi: 10.1016/j.euo.2018.09.003. Epub 2018 Oct 4. Eur Urol Oncol. 2019. PMID: 31411988 - A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll A, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA. Troyer DA, et al. Prostate. 2015 Aug 1;75(11):1206-15. doi: 10.1002/pros.23003. Epub 2015 May 4. Prostate. 2015. PMID: 25939393 Free PMC article. - Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.
Ross AE, D'Amico AV, Freedland SJ. Ross AE, et al. Prostate Cancer Prostatic Dis. 2016 Mar;19(1):1-6. doi: 10.1038/pcan.2015.31. Epub 2015 Jun 30. Prostate Cancer Prostatic Dis. 2016. PMID: 26123120 Review.
Cited by
- DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.
Cyll K, Skaaheim Haug E, Pradhan M, Vlatkovic L, Carlsen B, Löffeler S, Kildal W, Skogstad K, Hauge Torkelsen F, Syvertsen RA, Askautrud HA, Liestøl K, Kleppe A, Danielsen HE. Cyll K, et al. Br J Cancer. 2024 Sep;131(5):895-904. doi: 10.1038/s41416-024-02780-x. Epub 2024 Jul 3. Br J Cancer. 2024. PMID: 38961192 Free PMC article. - Simultaneous Thoracic Spine Metastatic Melanoma and Pre-existing Prostate Adenocarcinoma: A Unique Case Presentation and Literature Review.
Venkata SA, Hakobyan N, Yadav R, Pokhrel A, Jamal F, Oudit O, Boris A, Kay A. Venkata SA, et al. Cureus. 2023 Aug 13;15(8):e43429. doi: 10.7759/cureus.43429. eCollection 2023 Aug. Cureus. 2023. PMID: 37706116 Free PMC article. - Predicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.
Erak E, Oliveira LD, Mendes AA, Dairo O, Ertunc O, Kulac I, Baena-Del Valle JA, Jones T, Hicks JL, Glavaris S, Guner G, Vidal ID, Markowski M, de la Calle C, Trock BJ, Meena A, Joshi U, Kondragunta C, Bonthu S, Singhal N, De Marzo AM, Lotan TL. Erak E, et al. Mod Pathol. 2023 Oct;36(10):100247. doi: 10.1016/j.modpat.2023.100247. Epub 2023 Jun 10. Mod Pathol. 2023. PMID: 37307876 Free PMC article. - Correlations of PTEN and ERG Immunoexpression in Prostate Carcinoma and Lesions Related to Its Natural History: Clinical Perspectives.
Voulgari O, Goutas D, Pergaris A, Belogiannis K, Thymara E, Kavantzas N, Lazaris AC. Voulgari O, et al. Curr Issues Mol Biol. 2023 Mar 25;45(4):2767-2780. doi: 10.3390/cimb45040181. Curr Issues Mol Biol. 2023. PMID: 37185705 Free PMC article. - Association Between ERG/PTEN Genes and Pathologic Parameters of Prostate Cancer With an Emphasis on Gleason Score: A Literature Review.
Spinos T, Georgiou A, Voulgari O, Goutas D, Lazaris AC, Thymara I, Kavantzas N, Thomopoulou GE. Spinos T, et al. Cancer Diagn Progn. 2023 May 3;3(3):291-296. doi: 10.21873/cdp.10214. eCollection 2023 May-Jun. Cancer Diagn Progn. 2023. PMID: 37168967 Free PMC article. Review.
References
- Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 2012;118 (24:6063–6071. - PMC - PubMed
- Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS, Transatlantic Prostate Group Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27 (3:253–263. - PMC - PubMed
- Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, Ghosh PM. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res. 2007;13 (13:3860–3867. - PubMed
- Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate group study. Br J Cancer. 2009;100:888–893. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous